DRD2 and Parkinson disease: Similarly, striatal dopamine D2 receptor upregulation was observed in drug-naïve PD patients using SPECT ligands (123I-IBZM and 123I-IBF) probably suggesting compensatory changes secondary to nigrostriatal denervation, with higher upregulation detected in the posterior putamen (161, 240).